February 15th 2025
A review of 50 studies confirmed the safety and efficacy of radium-223 for metastatic castration-resistant prostate cancer treatment.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.
Read More
FDA Oks FoundationOne CDx and Liquid CDx for Use With Olaparib/Abiraterone in Prostate Cancer
September 4th 2024The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.
Read More